Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 - April 2019.
Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 - April 2019.
复制标题
DOI：
10.1080/21645515.2022.2079923
复制
发表时间：
2022-11-30
影响因子：
4.8
通讯作者：
中科院分区：
文献类型：
--
作者：
希腊于2010年将13价肺炎球菌结合疫苗（PCV 13）引入婴儿国家免疫计划（3 + 1计划，直至2019年6月）。自2015年以来，PCV 13已被推荐用于19 - 64岁患有合并症的成年人和≥ 65岁的成年人，序贯使用23价肺炎球菌多糖疫苗（PPSV23）。我们研究了2017年11月至2019年4月期间因社区获得性肺炎（CAP）住院的≥ 19岁希腊成年人中的肺炎球菌血清型分布。这是对EGNATIA的中期分析，EGNATIA是一项在约阿尼纳和卡瓦拉市住院的成人CAP的前瞻性研究。使用培养物、BinaxNow®、细菌型特异性尿抗原检测试验（UAD-1/2）鉴定肺炎球菌。我们的分析共包括482例住院CAP患者（平均年龄：70.5岁; 56.4%男性）。53.53%的患者属于肺炎严重程度指数（PSI）最高级别（IV-V）。在65例（13.5%）患者中检测到肺炎球菌，其中一半以上（57%）仅通过UAD检测到。大约三分之二的肺炎球菌CAP发生在年龄≥ 65岁的患者中（n = 40，8.3%的CAP）。超过一半的肺炎球菌CAP（n = 35，53.8%）由PCV 13血清型引起。最常检测到的PCV 13血清型为3、19 A、23 F，合计占PCV 13疫苗型（VT）CAP的83%和全因CAP的6%。总体而言，82.9%的PCV 13 VT CAP发生在有PCV 13疫苗接种适应症（基于年龄/风险）的人群中。即使有成熟的PCV 13儿童免疫接种计划，希腊成人中仍存在PCV 13 VT CAP的持续负担。应实施增加成人PCV 13（和获得许可的高效价PCV）覆盖率的策略，以减少疾病负担。希腊CAP住院成人前瞻性研究的中期分析。血清型特异性尿抗原检测试验用于检测肺炎球菌。在希腊成人中观察到PCV 13疫苗型CAP的持续负荷。改善PCV 13摄取和更高效价的PCV可降低肺炎球菌疾病负担。
Greece introduced a 13-valent pneumococcal conjugate vaccine (PCV13) into the infant national immunization program in 2010 (3 + 1 schedule until June 2019). Since 2015, PCV13 has been recommended for adults aged 19–64 years with comorbidities and adults ≥65 years sequentially with 23-valent pneumococcal polysaccharide vaccine (PPSV23). We examined pneumococcal serotype distribution among Greek adults aged ≥19 years hospitalized with community-acquired pneumonia (CAP) during November 2017-April 2019. This was an interim analysis of EGNATIA, a prospective study of adult hospitalized CAP in the cities of Ioannina and Kavala. Pneumococcus was identified using cultures, BinaxNow®, serotype-specific urinary antigen detection assays (UAD-1/2). Our analysis included overall 482 hospitalized CAP patients (mean age: 70.5 years; 56.4% male). 53.53% of patients belonged to the highest pneumonia severity index (PSI) classes (IV-V). Pneumococcus was detected in 65 (13.5%) patients, with more than half (57%) of cases detected only by UAD. Approximately two-thirds of pneumococcal CAP occurred in those aged ≥65 years (n = 40, 8.3% of CAP). More than half of pneumococcal CAP (n = 35, 53.8%) was caused by PCV13 serotypes. Most frequently detected PCV13 serotypes were 3, 19A, 23F, collectively accounting for 83% of PCV13 vaccine-type (VT) CAP and 6% of all-cause CAP. Overall, 82.9% of PCV13 VT CAP occurred among persons with an indication (age/risk-based) for PCV13 vaccination. Even with a mature PCV13 childhood immunization program, a persistent burden of PCV13 VT CAP exists in Greek adults. Strategies to increase PCV13 (and higher-valency PCVs, when licensed) coverage in adults should be implemented to reduce the disease burden. An interim analysis of a prospective study in adults hospitalized with CAP in Greece. Serotype-specific urinary antigen detection assays were used to detect pneumococcus. A persistent burden of PCV13 vaccine-type CAP was observed in Greek adults. Improved PCV13 uptake and higher-valency PCVs may reduce the pneumococcal disease burden.
登录
查看更多内容
影响因子：
3.5
作者：
Groves, Natalie;Sheppard, Carmen L.;Fry, Norman K.
通讯作者：
Fry, Norman K.
影响因子：
5.5
作者：
Grivea, Ioanna N.;Priftis, Kostas N.;Syrogiannopoulos, George A.
通讯作者：
Syrogiannopoulos, George A.
影响因子：
4.5
作者：
Maccioni, Livia;Weber, Susanne;Nieters, Alexandra
通讯作者：
Nieters, Alexandra
影响因子：
11.8
作者：
Harboe, Zitta Barrella;Dalby, Tine;Valentiner-Branth, Palle
通讯作者：
Valentiner-Branth, Palle
影响因子：
158.5
作者：
Fine, MJ;Auble, TE;Kapoor, WN
通讯作者：
Kapoor, WN